This invention relates to LY6G6F, VSIG10, TMEM25 and LSR proteins, which are suitable targets for immunotherapy, treatment of cancer, infectious disorders, and/or immune related disorders, and drug development. This invention further relates to soluble LY6G6F, VSIG10, TMEM25 and LSR molecules, extracellular domains ...

This invention relates to antibodies and antigen binding fragments and conjugates containing same and/or alternative scaffolds specific for LSR molecules which are suitable drugs for immunotherapy and treatment of specific cancer.

This invention relates to C10RF32 specific antibodies antibody fragments alternative scaffolds conjugates and compositions comprising same for treatment of cancer.

This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against KIAA0746, CD20 or CD55 antigens, which are differentially expressed in cancer and in specific blood cells, and diagno...

This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagNOsis. More particμlarly, the invention provides therapeutics antibothes against KRTCAP3, FAM26F, MGC52498, FAM70A or TMEM154 antigens, which are differentially expressed in cancer, and diagNOst...

The present invention is directed to anti PVRIG antibodies and methods of using same.

Anti-PVRIG and anti-TIGIT antibodies are provided.

Anti-PVRIG, anti-TIGIT, and anti-PVRIG/anti-TIGIT bispecific antibodies are provided, as well as compositions, and methods of using the antibodies for the treatment of cancer.

ABSTRACT “AN ANTI-PVRIG (POLIOVIRUS RECEPTOR RELATED LMMUNOGLOBULIN DOMAIN CONTAINING PROTEIN) ANTIBODY” The present invention relates to an anti-PVRIG (Poliovirus Receptor Related lmmunoglobulin Domain Containing Protein) antibody, wherein said anti-PVRIG antibody comprises: the following vhCDR1, vhCDR2, vh...

The present invention is directed to anti-IL18-BP antibodies and uses thereof. The present invention is directed to monotherapy and combination treatments with for example immune checkpoint inhibitor antibodies, as described herein.

The present invention provides formulations comprising anti-TIGIT antibodies with CDRs identical to those shown in Figure 3 (i.e., CDRs identical to those for CPA.9.086.H4(S241P), as described herein.